transfusionfatalities

DeathsreportedtotheFDAincludedonorfatalities,recipientfatalitiesinwhichallogeneicbloodtransfusion(ABT)wasnotdeemedtobethelikelyormajor ...,由EKStorch著作·2020·被引用31次—MostABO-incompatibleRBCtransfusionsarenotfatalbutmaybeassociatedwithsignificantcomplications.Inourpreliminaryanalysisof ...,由EKStorch著作·2020·被引用31次—TherateofreportedfatalitiesfromABO-incompatibleRBCtransfusionhassignifi...

參考資訊如下
Transfusion-related mortality

Deaths reported to the FDA include donor fatalities, recipient fatalities in which allogeneic blood transfusion (ABT) was not deemed to be the likely or major ...

Trend in ABO‐incompatible RBC transfusion‐related ...

由 EK Storch 著作 · 2020 · 被引用 31 次 — Most ABO-incompatible RBC transfusions are not fatal but may be associated with significant complications. In our preliminary analysis of ...

Trend in ABO-incompatible RBC transfusion

由 EK Storch 著作 · 2020 · 被引用 31 次 — The rate of reported fatalities from ABO-incompatible RBC transfusion has significantly decreased in the past decade.

Blood transfusion associated fatalities

由 MV Jadhav 著作 · 2000 · 被引用 6 次 — 3 deaths could not be attributed to transfusion reaction. Post transfusion endotoxaemia (7 cases) was the most frequent mode of transfusion associated fatality ...

FDA Releases 2021 Report on Fatalities Following Blood ...

2023年9月29日 — In FY 2021, the leading cause of transfusion-related fatalities was transfusion-associated circulatory overload (TACO), accounting for 36 ...

Fatalities Reported to FDA Following Blood Collection and ...

Fatalities previously defined as not transfusion/donation related continue to be classified as ruled out. To achieve a more comprehensive review, we added three ...

TransfusionDonation Fatalities

2023年9月22日 — Annual Summary Fatalities Reported to FDA Following Blood Collection and Transfusion older than 2 years are available on FDA ArchiveExternal ...

Risks of Blood Transfusion Fatalities Reported to FDA ...

Immunologic Complications, Immediate. 1. Hemolytic transfusion reaction (incidence: 1:12,000 to 1:38,000). 2. Immune mediated platelet destruction ...